Targeted Oncology (@TargetOncology) header
Targeted Oncology (@TargetOncology) profile picture

A Journal for oncologists and cancer scientists, distributing clinical and molecular information to decision makers involved in targeted therapies in oncology

Joined September 2016
Photo by Targeted Oncology (@TargetOncology)Photo by Targeted Oncology (@TargetOncology)Photo by Targeted Oncology (@TargetOncology)Photo by Targeted Oncology (@TargetOncology)Photo by Targeted Oncology (@TargetOncology)Photo by Targeted Oncology (@TargetOncology)Photo by Targeted Oncology (@TargetOncology)Photo by Targeted Oncology (@TargetOncology)Photo by Targeted Oncology (@TargetOncology)Photo by Targeted Oncology (@TargetOncology)
Targeted Oncology retweeted
An infographic has been added to this open access paper link.springer.com/article/10…
1
1
Our Medicine Matters Oncology journal club highlights publications each month from our key titles @TargetOncology, @AdvancesTherapy and more.
This Post is from an account that no longer exists. Learn more
2
1
Targeted Oncology retweeted
Recently published in Targeted Oncology, an independently written Adis Drug Evaluation on gilteritinib in relapsed or refractory FLT3-mutated acute myeloid leukaemia. Read the article here: link.springer.com/article/10… #leukemia
Exciting #news for Oncology and Therapy... The journal is now indexed on #PubMed All articles from and including June 2018 are now indexed on the site: buff.ly/2OS26lA #cancer #oncology #openaccess
1
22
7
27
Brain Penetration of #Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive #NSCLC link.springer.com/article/10…
2
3
Call For Papers Oncology and Therapy has an active call for papers. Publish your original research, reviews, patient related papers and more. Fully #openaccess with rapid timelines, brought to you by Adis (part of #SpringerHealthcare) springer.com/journal/40487/ for more info
1
12
3
Targeted Oncology retweeted
The Adis Team will be attending #ISMPPEU20 next week and are really looking forward to meeting you. Please come and visit us at Stand 2 and be in with the chance to win an Amazon Kindle! #Adis #Publishing #openaccess
Targeted Oncology retweeted
Another reason to submit to this fully open access journal
Drugs in R&D has been accepted into the SCIE from Clarivate and will receive its official impact factor this year (2020).
1
1
Model-Based #Cost #Effectiveness Analysis of #Panitumumab Plus FOLFIRI for the Second-Line #Treatment of #Patients with Wild-Type Ras #Metastatic #Colorectal #Cancer buff.ly/2ZWQsuj
Read our newly published Letters to the Editor: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China buff.ly/2FrCZRE And the response letter: buff.ly/37HyheU
1
1
Just published: The Effect of #Rifampin on the #Pharmacokinetics and Safety of #Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants buff.ly/2Q21p9k
#Observational Study of Sequential #Afatinib and #Osimertinib in #EGFR Mutation-Positive #NSCLC: #Patients Treated with a 40-mg Starting Dose of Afatinib buff.ly/36YAySv
2
1
Targeted Oncology retweeted
Huge news for #bladdercancer with new agent (EV) approved! More to come! Good to look ORR & outcomes with EV in pts with FGFR alterations! Field moving forward @BladderCancerUS @IBCG_BladderCA @IBCN1997 @bladderau @ArjunBalarMD @MattGalsky @FDAOncology @ERPlimackMD @apolo_andrea
1
50
5
89
Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic #UrothelialCarcinoma link.springer.com/article/10… #ADC
Targeted Oncology retweeted
Published this year in Targeted Oncology, results of pre-specified and post hoc analyses of the phase III ARAMIS trial with an accompanying Plain Language Summary buff.ly/35fVIuj #openaccess #esmo19 #darolutamide #prostratecancer #plainlanguagesummary #PLS
Targeted Oncology retweeted
Please join Network Pharma’s ‘Meet the publishers’ panel on 4th December, where Caroline Halford (Adis Digital Publishing Manager) will be co-hosting a session on current and future trends in medical publishing #medcomms Register here: zoom.us/webinar/register/WN_…
11
3
Online now: Clinicians’ #Perspectives on Cure in Adult Patients with Acute Lymphoblastic #Leukemia with Minimal Residual Disease: A Delphi Study Read the associated Plain Language Summary for this article below, and access the full article online here: buff.ly/320zmfq
Indirect Treatment Comparison of #Nivolumab Versus Observation or #Ipilimumab as Adjuvant Therapy in Resected #Melanoma Using Pooled Clinical Trial Data buff.ly/2UcyDEB
Existing and Emerging #Biomarkers for Immune #Checkpoint #Immunotherapy in Solid #Tumors buff.ly/2zel6me
Maintenance Versus Intermittent Strategies in the Treatment of #Metastatic #Colorectal #Cancer:A Meta-Analysis from Another Angle buff.ly/2KY8vcz